Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Collost is a native bovine Type I collagen biomaterial developed and manufactured by Nearmedic Plus. It is designed to act as a structural scaffold that promotes tissue regeneration and repair by facilitating fibroblast migration and the synthesis of new endogenous collagen. The product is available in various forms, including an injectable gel (typically in 7% and 15% concentrations) and topical membranes or sponges. It is widely utilized in clinical applications across dermatology and cosmetology for the correction of atrophic scars, stretch marks, and age-related skin changes. Additionally, it is used in surgery for chronic wound healing and pressure sores, and in dentistry for periodontal tissue restoration. The material is processed using a proprietary technology that preserves the native triple-helix structure of collagen, ensuring biocompatibility and effective integration into the host tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Collost.